Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
I want to let you in on a secret.
It's the greatest untold story in the stock market today.
The mainstream media ought to be covering this story aggressively - yet I've hardly heard a word about it.
Perhaps it's because the facts I'm about to share with you contradict the impending "tech bubble" the financial media has been gleefully speculating about for the last year or so.
However, here's the real story: The valuations of tech stocks are still grounded in reason - and tech stocks as a group absolutely crushed the overall market in this year's first quarter.
So, today I'll show you precisely how high tech is flattening everything in its path.
And then we'll talk about ways to make some money while everyone else is distracted by "bubble talk"...
Knockout Punch
During the first quarter, the tech-centric Nasdaq Composite Index beat the bellwether Dow Jones Industrial Average by 656%.
No doubt some of you may say comparing the Nasdaq to the Dow is not a fair fight. And that's partially true.
The Dow contains just 30 of the nation's mega-cap stocks, including new entrant Apple Inc. (Nasdaq: AAPL).
With Apple as a key exception, it mostly holds stocks that people count on for their stability, not rapid price appreciation.
For its part, the Nasdaq is much more a growth story. It's brimming with younger, more aggressive firms in growth fields like biotech, the mobile revolution, cloud computing, Big Data, and the connected car.
However, even if we ignore the Dow, tech is still the biggest driving force in stocks today - the Nasdaq in the first quarter beat the S&P 500 by 268%.
In the first quarter, the Nasdaq gained 4.16%. That compares with first-quarter profits of 1.13% for the S&P and a mere 0.55% for the Dow.
True, it's always possible that tech just got lucky and had a strong first quarter.
Except that the empirical data conclusively proves just what I've been saying ever since I launched this service two years ago.
That's when I said that tech stocks will almost always beat the overall market - and I just reiterated that when I created "The Million-Dollar Tech Portfolio."
Just look at the data when I compare the Nasdaq Composite with the S&P:
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
